Androgen assessment is a key element for diagnosing polycystic ovary syndrome (PCOS), and defining a “normal” level of circulating androgens is critical for epidemiological studies. We determined the upper normal limits (UNLs) for androgens in a population-based group of premenopausal “healthy control” women, overall and by ethnicity (Caucasian and Asian), in the cross-sectional Eastern Siberia PCOS Epidemiology and Phenotype (ESPEP) Study (ClinicalTrials.gov ID: NCT05194384) conducted in 2016–2019. Overall, we identified a “healthy control” group consisting of 143 healthy premenopausal women without menstrual dysfunction, hirsutism, polycystic ovaries, or medical disorders. We analyzed serum total testosterone (TT) by using liquid chromatography with tandem mass spectrometry (LC-MS/MS), and DHEAS, sex-hormone-binding globulin (SHBG), TSH, prolactin, and 17-hydroxyprogesterone (17OHP) were assessed with an enzyme-linked immunosorbent assay (ELISA). The UNLs for the entire population for the TT, free androgen index (FAI), and DHEAS were determined as the 98th percentiles in healthy controls as follows: 67.3 (95% confidence interval (CI): 48.1, 76.5) ng/dl, 5.4 (3.5, 14.0), and 355 (289, 371) μg/dl, respectively. The study results demonstrated that the UNLs for TT and FAI varied by ethnicity, whereas the DHEAS UNLs were comparable in the ethnicities studied.
23 August 2018 in Annals of the Russian academy of medical sciences
Background: Information about involvement of general nonspecific reactions, in particular lipid peroxidation processes, in the progression of varicose veins of the pelvic (VVP) in women is still too scarce. Aims: To study the intensity of processes of lipid peroxidation and the activity of components of the antioxidant system in women with primary varicose veins of the pelvic at different stages of the disease. Materials and methods: 167 women of reproductive age were examined ― 137 with VVP and 30 made up a control group. All patients with VVP were divided into 3 groups depending on stages of the disease. Spectrophotometric and fluorometric methods of investigation were used. The study was conducted during 2012−2017. Results: It was revealed that the level of primary products of lipid peroxidation, diene conjugates, increased statistically significantly according to the stage of the disease by 1.25 times (in the 1st stage), 1.51 times (in the II stage) and 1.59 times (in the III stage) values. Changes in the content of final TBA-active products showed similar changes-an increase in the mean values for all stages of the disease relative to control (in 1.24, 1.17, and 1.77 times, respectively). Activity of glutathione peroxidase increased in stage 2 of VVP (1.19 times), with the maximum increase in stage III (1.42 times); activity of glutathione-S-transferase increased 1.18 times in the II stage of the disease. The concentration of GSH in the clinical groups was characterized by lower values with respect to the control (by 1.22 times in the 1st stage, in 1.64 times in the II stage), with the maximum decrease of this parameter in the III stage of VVP (3.67 times). The level of catalase activity increased in the I stage of VVP ― by 1.18 times and decreased in the III stage ― by 1.14 times with respect to the control. The activity of SOD showed similar changes with catalase ― in the form of increased activity at the 1st stage (1.35 times higher) and decreased values for II (1.35 times lower) and III (1.65 times lower) for the stages of VVP to the values of control. Conclusions: At progression of primary VVP in women (from the initial stage to the 3rd stage of the disease), there is an increase in imbalance in the lipid peroxidation − antioxidant defense system. Moreover, if the compensatory increase in activity of antioxidant enzymes is registered at stage 1 of the disease, then the most of the antioxidant defense factors decreases as relative to control values, and the initial stages of the disease.
Leydig cell tumors (LCTs) refer to tumors of the stroma of the genital strand, which are found mainly in postmenopausal women. The diagnosis of LCTs in postmenopausal women is associated with specific difficulties and is based on the identification of hyperandrogenism with clinical manifestations of virilization, which has an erased picture in postmenopausal women. LCTs require differential diagnosis with other causes of hyperandrogenism. We present the clinical case of a 55-year-old Russian postmenopausal patient with LCTs of the right ovary, significantly increased levels of androgens, and rapidly progressive clinical signs of hyperandrogenism. The patient underwent laparoscopic bilateral salpingo-oophorectomy, and the androgen indices reached average values by the first and third month after surgery. This case demonstrates that LCTs are often benign with a good prognosis and normalization of the clinical and laboratory manifestations of hyperandrogenism after surgical treatment. The type of surgery performed (bilateral salpingo-oophorectomy rather than unilateral) is recommended as the treatment of choice for LCTs in postmenopausal patients.
Polycystic ovary syndrome (PCOS) is the most common cause of female endocrine infertility. Insulin resistanсе is supposed to be one of the essential factors of this disease pathways. At the same time, the mechanisms of PCOS development in insulin-resistant patients have not been completely established. Leptin and Peroxisome Proliferator-Activated Receptor γ(PPARγ) are involved in carbohydrate metabolism and reproduction function regulation. It indicates that leptin and PPARγ possibly play a role in the pathways of PCOS. This article is a review of publications on this issue. The purpose of this review was to systematize the available information on the molecular mechanisms that determine the role of leptin and PPARγ in the development of PCOS. The literature search was carried out from 04/05/2020 to 05/17/2020 using the scientific literature databases: NCBI PubMed (foreign sources) and Cyberleninka (domestic sources). We analyzed publications for the period 1990-2020.The review presents the current understanding of the possible role of leptin and PPARγ in the regulation of endocrine, immune systems, and reproductive function, as well as in the development of PCOS. Currently, no studies cover the mechanisms of interaction between leptin and PPARγ in the pathways of this syndrome. The available studies indicating the individual contribution and association of leptin and PPARγ with PCOS are conflicting and have many limitations. Therefore, more studies of direct and indirect interaction of leptin and PPARγ, as well as their role in PCOS pathways, are needed.